To distinguish measurements of inflammasome-associated biomarkers from assessments of immune cells’ functional capacity to activate the NLRP3 inflammasome in sepsis.
Approach:
Commentary: The authors discuss Neumann et al.’s review and prior studies of NLRP3 inflammasome activity in sepsis and critical illness.
Proposed assessment: They advocate complementing circulating biomarker measurements with ex vivo functional assays that test responses to a defined NLRP3 challenge.
Key Findings:
Circulating IL-1β, IL-18, GSDMD, caspase-1, ASC specks, and transcriptional signatures provide evidence related to inflammasome activity but do not necessarily measure immune-cell responsiveness.
In one study, septic patients’ monocytes had impaired ex vivo NLRP3 activation despite persistent systemic inflammation; the impairment was linked to mitochondrial dysfunction, reduced caspase-1 activation, and defective IL-1β maturation.
Circulating inflammatory markers, including ASC specks, did not predict the reported functional abnormalities.
A subsequent study associated altered ex vivo NLRP3 activation with higher 28-day mortality among septic patients.
Inflammasome responses may vary between patients and over disease progression, including across hyperinflammatory and immunosuppressive states.
Interpretation:
The authors argue that ex vivo functional NLRP3 assessment could complement circulating biomarkers by characterizing inflammasome responsiveness as hyperresponsive, balanced, or refractory.
Limitations:
The article is a commentary drawing on a review and prior studies, rather than a report of a new clinical study.
The context does not provide study sample sizes, assay protocols, or detailed effect estimates.
Conclusion:
The authors propose incorporating functional ex vivo NLRP3 assays into future inflammasome-guided approaches to patient stratification and precision immunomodulation in sepsis.
